Answers are grounded in this paper and cite their sources.
Preclinical study demonstrates robust type I reactive oxygen species generation and antitumor efficacy using a platinum photosensitizer, suggesting potential for hypoxia-tolerant cancer therapy.
Conventional photodynamic therapy (PDT) suffers from aggregation-caused quenching and high oxygen dependence. Herein, we report a platinum (Pt)-coordinated photosensitizer (TPAQPt) for hypoxia-tolerant PDT. Inheriting aggregation-induced emission (AIE) features, high spin orbital coupling and intramolecular charge transfer ability, TPAQPt exhibits robust type I reactive oxygen species generation and a promising antitumor PDT effect.
No takes yet. Share an insight, caveat, or question.
Liang et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: